Aleniglipron’s tolerability could be a differentiator for Structure Therapeutics, but its efficacy lags competitors. Read why I maintain a Hold on GPCR stock.
Structure Therapeutics: Why Aleniglipron’s Path To Market Remains Treacherous
view original post